샘플 요청 목록

 카트 문의
시장보고서
상품코드
1659437

세계의 골관절염 치료제 시장

Osteoarthritis Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 84 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 골관절염 치료제 시장은 2030년까지 158억 달러에 이를 전망

2024년에 104억 달러에 이른 것으로 추정되는 골관절염 치료제 세계 시장은 2024-2030년 분석 기간에 CAGR 7.3%로 성장하여 2030년에는 158억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 무릎 해부학은 CAGR 8.1%를 나타내고, 분석 기간 종료시에는 71억 달러에 이를 것으로 예측됩니다. 고관절 해부학 부문의 성장률은 분석 기간에 CAGR 7.3%로 추정됩니다.

미국 시장은 27억 달러로 추정, 중국은 CAGR 10.8%로 성장 예측

미국의 골관절염 치료제 시장은 2024년에 27억 달러에 이른 것으로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 38억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년간 CAGR은 10.8%를 나타낼 전망입니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 3.6%와 6.7%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 CAGR 4.5%로 성장할 것으로 예측됩니다.

세계의 골관절염 치료제 시장 - 주요 동향과 성장 촉진요인 정리

왜 골관절염 치료제는 점점 더 커지는 건강 문제를 관리하는 데 필수적인가?

퇴행성 관절염(OA) 치료제는 퇴행성 관절 질환을 앓고 있는 인구가 급증함에 따라 그 수요를 충족시키는 데 필수적인 역할을 하고 있습니다. 골관절염은 관절의 연골 파괴와 그로 인한 염증으로 특징지어지며, 만성적인 통증, 뻣뻣함, 운동 제한을 유발하여 삶의 질에 큰 영향을 미치는 질환입니다. 주로 무릎, 허리, 척추 등 체중이 실리는 관절을 침범하며, 고령자나 비만인, 관절 손상을 입은 사람에게 특히 많이 발생합니다. 세계 인구의 고령화에 따라 OA 환자가 급증하면서 통증 관리, 관절 기능 개선, 질병 진행을 지연시키는 치료제에 대한 수요가 증가하고 있습니다. 골관절염 치료제에는 진통제, 비스테로이드성 항염증제(NSAIDs), 코르티코스테로이드, 히알루론산 주사, 그리고 최근에는 첨단 생물학적 치료법 등 다양한 치료법이 있습니다.

통증 관리는 OA가 노인의 만성 통증의 주요 원인이기 때문에 골관절염 치료제의 주요 목적 중 하나입니다. 비스테로이드성 항염증제나 아세트아미노펜은 통증과 염증을 억제하는 효과가 있어 널리 사용되고 있지만, 부작용을 동반하는 경우가 많아 장기간 사용에는 한계가 있습니다. 따라서 부작용 없이 지속적인 통증 완화를 가져다주는 대체 치료제에 대한 니즈가 높아지면서 OA 치료제 시장의 기술 혁신을 주도하고 있습니다. 통증 관리뿐만 아니라 골관절염의 근본적인 원인을 해결하기 위한 질병 변형성 골관절염 치료제(DMOADs)의 개발도 진행되고 있습니다. 이러한 치료제는 연골을 보호하고, 염증을 억제하고, 관절 기능을 회복시킬 수 있으며, 골관절염을 관리하기 위한 보다 종합적인 접근법을 제공하는 것을 목표로 하고 있습니다. 장기적인 질환 개선과 통증 완화에 초점을 맞춘 골관절염 치료제는 중요한 연구 분야로 자리매김하고 있으며, 증상과 삶의 질을 더 잘 관리하고자 하는 환자들에게 희망을 주고 있습니다.

또한, OA 치료제는 비용, 회복 시간, 합병증 가능성으로 인해 최후의 수단으로 여겨지는 인공관절 치환술을 예방하는 중요한 역할을 하고 있습니다. 약리학적 및 생물학적 치료를 통해 OA 증상을 효과적으로 관리함으로써 수술의 필요성을 늦출 수 있고, 환자에게 덜 침습적인 치료법을 제공할 수 있습니다. 이는 의료 시스템이 선택적 수술과 그에 따른 비용 부담을 줄이기 위해 노력하고 있는 상황에서 특히 중요해지고 있습니다. 골관절염 치료제는 환자의 통증을 완화하고 이동성을 개선함으로써 골관절염을 관리하고 질환의 진행을 늦추는 적극적인 접근법을 지원하여 환자가 가능한 한 오랫동안 독립적인 생활을 유지하고 삶의 질을 유지할 수 있도록 돕습니다.

첨단 생물학적 치료는 골관절염 치료의 미래를 어떻게 형성하고 있을까?

첨단 생물학적 치료의 등장은 세포 수준에서 질병을 표적으로 삼고 진행을 교정할 수 있는 치료법을 도입함으로써 골관절염 치료제의 전망을 재구성하고 있습니다. 다혈소판 혈장(PRP), 줄기세포 치료, 단클론 항체와 같은 생물학적 치료법은 증상을 완화하고, 염증을 억제하며, 손상된 연골을 재생시킬 수 있는 새로운 접근법을 제공합니다. 환자 자신의 혈액에서 유래한 PRP를 환부의 관절에 주입함으로써 조직 회복을 촉진하는 성장인자에 의해 치유를 촉진하고 염증을 억제합니다. 간엽줄기세포를 이용한 줄기세포 치료는 연골 조직에 분화 가능한 세포를 도입하여 연골 재생을 목표로 합니다. 아직 실험 단계에 있지만, 이러한 생물학적 제제는 유망한 결과를 가져와 OA 환자에게 최소 침습적 치료 옵션을 제공하고 기존 치료와 비교하여 더 장기적인 효과를 가져올 수 있습니다. 이러한 치료법이 널리 보급되면 OA에 숨어있는 병태를 다루는 보다 효과적이고 표적화된 치료가 가능해질 것으로 기대됩니다.

특히 인터루킨-1(IL-1)이나 종양괴사인자(TNF)와 같은 염증성 사이토카인을 표적으로 하는 단클론항체는 골관절염 치료제의 또 다른 중요한 진전입니다. 이러한 항체는 연골 분해와 관절 염증을 유발하는 염증 경로를 차단함으로써 작용하며, OA에 관여하는 특정 단백질을 표적으로 삼음으로써, 단클론항체는 전신 부작용을 최소화하고 장기적인 완화를 가져오는 정확한 접근법을 제공합니다. 예를 들어, 인터루킨-1 수용체 길항제는 특히 무릎 골관절염 환자에서 염증을 억제하고 OA의 진행을 지연시킬 수 있는 가능성을 보여주었습니다. 이러한 표적 치료제의 효능이 임상시험에서 계속 입증됨에 따라, 특히 중증 및 진행성 골관절염 환자의 경우 OA 관리 방식을 근본적으로 바꿀 수 있는 질병 변형 치료에 대한 기대가 높아지고 있습니다.

유전자 치료는 골관절염 치료의 또 다른 새로운 분야로, 유전자 발현을 변화시켜 염증을 억제하고 연골의 회복을 촉진하는 데 초점을 맞추었습니다. 유전자 치료는 특정 유전자를 관절 조직에 도입하여 염증성 사이토카인을 억제하거나 연골 재생을 촉진하는 치료용 단백질을 생산하게 하는 것으로, 아직 초기 단계이지만 1회 치료로 지속적인 완화와 질환의 개선을 기대할 수 있습니다. 유전자 치료와 맞춤 의료의 융합은 OA 치료제 시장의 발전을 촉진하고 질병 진행에 기여하는 개별 유전적 요인에 대응하는 환자별 맞춤 치료를 제공할 것으로 기대됩니다. 이러한 생물학적 치료법이 성숙해짐에 따라 OA 치료의 개별화 및 재생 접근법으로의 전환이 진행되어 기존 치료법으로는 선택이 제한적인 환자들의 미충족 수요를 충족시킬 수 있을 것으로 기대됩니다.

골관절염 치료제는 환자와 의료 시스템에 어떤 이점이 있는가?

골관절염 치료제는 만성 통증을 관리하고 관절 기능을 개선하며 독립성을 유지하는 데 도움을 주어 환자들에게 큰 이점을 제공합니다. 통증 완화는 OA 치료의 핵심입니다. 통증 완화는 OA 치료제의 주요 이점이며, 환자는 불편함을 줄이면서 일상생활을 영위할 수 있습니다. 비스테로이드성 항염증제(NSAIDs), 부신피질 스테로이드, 진통제는 통증 관리를 위한 일반적인 선택이며, 빠른 완화를 가져와 환자가 더 나은 삶의 질을 유지할 수 있도록 도와줍니다. 심한 OA 환자의 경우, 히알루론산과 같은 주사 치료는 관절을 윤활하고 마찰을 줄이며 충격 흡수를 개선하는 데 도움이 됩니다. 통증과 염증을 완화함으로써 OA 치료제는 관절 건강과 전신 건강을 위해 필수적인 신체 활동을 가능하게 합니다.

통증 관리 외에도 DMOADs, 생물학적 제제, 재생 치료와 같은 새로운 골관절염 치료제는 질병의 진행을 교정하고 손상된 관절 조직을 회복시킬 수 있는 가능성을 목표로 하고 있습니다. 이러한 치료는 연골의 퇴화를 늦추거나 막는 장기적인 이점이 있어 인공관절 치환술의 필요성을 줄이고 관절의 안정성을 향상시킬 수 있습니다. 환자 입장에서는 침습적 시술을 줄이고, 회복 시간을 단축하며, 수술과 재활에 소요되는 의료 비용을 절감할 수 있으며, 현재 개발 중인 DMOADs는 OA의 궤도를 바꿀 수 있는 치료법에 대한 미충족 수요를 충족시키고, 환자들에게 증상 완화 이상의 옵션을 제공할 것으로 기대됩니다. 제공할 수 있을 것으로 기대되고 있습니다. 질병 변형 치료제가 출시되면 관절 기능, 이동성, 통증 관리의 지속적인 개선이 기대되며, OA 치료에 대한 보다 종합적인 접근법을 제공할 수 있을 것으로 기대됩니다.

의료 시스템 입장에서는 만성질환 관리와 선택적 수술의 부담을 줄여 비용 절감 효과를 기대할 수 있습니다. OA 치료제는 OA 증상을 효과적으로 관리하고 질병의 진행을 지연시킴으로써, 특히 OA가 가장 많이 발생하는 노인 집단에서 인공관절 치환술의 필요성을 지연시키거나 예방할 수 있습니다. 이렇게 수술의 필요성을 줄이면 의료 시스템에 대한 압박이 줄어들어 다른 필요한 분야에 자원을 할당할 수 있게 됩니다. 또한, 생물학적 제제 및 개인 맞춤형 치료의 발전은 환자의 예후를 개선하고 병원 재입원을 감소시켜 의료비 절감에 기여할 것으로 기대됩니다. 전 세계 의료 시스템이 만성 질환 관리를 위한 비용 효율적인 솔루션을 찾고 있는 가운데, 골관절염 치료제는 의료 자원 배분을 최적화하면서 환자 결과를 개선할 수 있는 실용적인 접근법을 제공합니다.

골관절염 치료제 시장의 성장을 가속하는 요인은 무엇인가?

골관절염 치료제 시장의 성장은 골관절염 유병률 증가, 치료 옵션의 발전, 최소침습적 치료에 대한 수요 증가, 세계 인구의 고령화 등 몇 가지 중요한 요인에 기인합니다. 평균 수명이 계속 늘어남에 따라 OA는 특히 관절 퇴행성 및 기타 노화 관련 질환에 취약한 노년층에서 더욱 흔하게 발생하고 있습니다. 이러한 인구 통계학적 변화로 인해 OA 치료제에 대한 수요가 크게 증가하고 있으며, 노인들은 삶의 질을 유지하기 위해 효과적인 통증 관리 및 이동성 솔루션을 찾고 있습니다. 보다 효과적이고 타겟팅된 치료법에 대한 연구개발에 대한 투자가 촉진되고 있습니다.

DMOADs, 줄기세포 치료, 단클론 항체의 개발은 환자와 의료진에게 증상 완화를 넘어 질병의 경과를 변화시키는 것을 목표로 하는 치료법, 특히 생물학적 제제 분야의 발전도 시장 성장에 기여하고 있습니다. 이러한 첨단 치료법은 질병의 진행을 늦추거나 역행시킬 수 있고, 침습적 치료의 필요성을 줄이고 장기적인 완화를 가져다 줄 수 있어 환자와 의료진 모두에게 관심을 받고 있습니다. 이러한 혁신적인 치료법은 특히 기존 치료법으로 효과를 보지 못한 환자들에게 매력적이기 때문에 OA 치료제 시장 수요는 더 널리 보급되고 가격이 저렴해짐에 따라 더욱 증가할 것으로 예상됩니다.

또한, 최소침습적 수술과 환자 맞춤형 치료의 발전은 첨단 OA 치료제의 채택을 촉진하고 있습니다. 환자들은 일상 생활에 지장을 최소화하면서 효과적인 증상 관리를 제공하는 치료를 원하고 있으며, PRP나 줄기세포 치료와 같은 생물학적 주사는 외래에서 시행할 수 있는 최소 침습적 치료 옵션을 제공함으로써 이러한 수요에 부응하고 회복 시간을 단축할 수 있게 합니다. 비수술적, 저침습적 치료에 대한 선호도가 높아지면서 제약회사와 의료 서비스 제공업체들은 환자의 경험과 치료 결과를 개선할 수 있는 OA 대체 요법에 대한 투자를 늘리고 있습니다. 또한, 정부의 이니셔티브와 새로운 치료법에 대한 보험 적용은 시장 성장을 가속하고 더 많은 환자들이 첨단 치료법을 더 쉽게 이용할 수 있도록할 것으로 예상됩니다. 고령화, 치료 옵션의 발전, 최소침습적 치료에 대한 수요, 의료 정책의 지원 등 이러한 요인들이 결합하여 골관절염 치료제 시장은 크게 성장하고 있으며, 현대 의료에 필수적인 역동적인 영역으로 형성되고 있습니다.

부문

해부학(슬관절, 고관절, 손관절, 소관절), 약제 유형(관절내 보충요법제, 비스테로이드성 항염증제, 진통제, 부신피질 스테로이드제)

조사 대상 기업 예(총 23개사)

  • Abbott
  • Anika Therapeutics
  • Bayer AG
  • Bioventus
  • Eli Lilly
  • Fidia Farmaceutici s.p.a.
  • Flexion Therapeutics
  • GlaxoSmithKline Plc
  • Horizon Therapeutics
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Sanofi
  • Zimmer Biomet Holdings, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.03.13

Global Osteoarthritis Therapeutics Market to Reach US$15.8 Billion by 2030

The global market for Osteoarthritis Therapeutics estimated at US$10.4 Billion in the year 2024, is expected to reach US$15.8 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Knee Anatomy, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$7.1 Billion by the end of the analysis period. Growth in the Hip Anatomy segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 10.8% CAGR

The Osteoarthritis Therapeutics market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Osteoarthritis Therapeutics Market - Key Trends & Drivers Summarized

Why Are Osteoarthritis Therapeutics Critical in Managing a Growing Health Concern?

Osteoarthritis (OA) therapeutics have become essential in addressing the needs of a rapidly growing population affected by this degenerative joint disease. Osteoarthritis, characterized by the breakdown of cartilage and the resultant inflammation in joints, leads to chronic pain, stiffness, and mobility limitations that significantly impact quality of life. It primarily affects weight-bearing joints like the knees, hips, and spine, and is especially prevalent among the aging population, as well as individuals with obesity or those who have sustained joint injuries. As the global population ages, OA cases have surged, creating an increased demand for therapeutics that can manage pain, improve joint function, and slow disease progression. Osteoarthritis therapeutics encompass a range of treatments, including analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, hyaluronic acid injections, and, more recently, advanced biological treatments.

Pain management is one of the primary objectives in osteoarthritis therapeutics, as OA is a leading cause of chronic pain among older adults. NSAIDs and acetaminophen are widely used for their effectiveness in reducing pain and inflammation, but they often come with side effects that limit their long-term use. As a result, there is a growing need for alternative treatments that offer sustainable pain relief without adverse effects, driving innovation in the OA therapeutics market. Beyond pain management, disease-modifying osteoarthritis drugs (DMOADs) are increasingly being developed to address the underlying causes of OA. These therapies aim to protect cartilage, reduce inflammation, and potentially restore joint function, offering a more comprehensive approach to managing OA. The focus on long-term disease modification and pain relief has positioned osteoarthritis therapeutics as a crucial area of research, providing hope for patients seeking better management of their symptoms and quality of life.

Additionally, OA therapeutics play a critical role in preventing joint replacement surgeries, which are often seen as a last resort due to the costs, recovery time, and potential complications involved. Effective management of OA symptoms through pharmacological and biological treatments can delay the need for surgery, providing patients with less invasive options for managing their condition. This has become especially important as healthcare systems seek to reduce the burden of elective surgeries and their associated costs. By offering patients relief from pain and improved mobility, osteoarthritis therapeutics support a proactive approach to managing OA and delaying disease progression, helping patients maintain independence and a higher quality of life for as long as possible.

How Are Advanced Biological Therapies Shaping the Future of Osteoarthritis Treatment?

The advent of advanced biological therapies is reshaping the osteoarthritis therapeutics landscape by introducing treatments that target the disease at a cellular level, with the potential to modify its progression. Biological therapies, including platelet-rich plasma (PRP), stem cell therapy, and monoclonal antibodies, offer new approaches for alleviating symptoms, reducing inflammation, and potentially regenerating damaged cartilage. PRP, derived from the patient’s own blood, is injected into the affected joint to stimulate healing and reduce inflammation through growth factors that promote tissue repair. Stem cell therapy, which uses mesenchymal stem cells, aims to regenerate cartilage by introducing cells capable of differentiating into cartilage tissue. Although still in the experimental stage, these biologics offer promising results, providing OA patients with minimally invasive options that may offer longer-lasting benefits compared to traditional treatments. As these therapies gain traction, they are expected to provide more effective, targeted treatments that address OA’s underlying pathology.

Monoclonal antibodies, specifically those targeting inflammatory cytokines like interleukin-1 (IL-1) and tumor necrosis factor (TNF), represent another significant advancement in osteoarthritis therapeutics. These antibodies work by blocking the inflammatory pathways that contribute to cartilage degradation and joint inflammation. By targeting specific proteins involved in OA, monoclonal antibodies offer a precise approach that minimizes systemic side effects and provides long-term relief. For example, interleukin-1 receptor antagonists have shown potential in reducing inflammation and slowing the progression of OA, especially in patients with knee osteoarthritis. As clinical trials continue to demonstrate the efficacy of these targeted therapies, they offer hope for disease-modifying treatments that could fundamentally change how OA is managed, particularly for patients with severe and progressive forms of the disease.

Gene therapy is another emerging field in osteoarthritis treatment, focusing on altering gene expression to reduce inflammation and stimulate cartilage repair. Gene therapies introduce specific genes into joint tissues to produce therapeutic proteins that may inhibit inflammatory cytokines or enhance cartilage regeneration. Although gene therapy for OA is still in its early stages, it holds the potential for one-time treatments that could offer sustained relief and disease modification. The convergence of gene therapy and personalized medicine is expected to drive advancements in the OA therapeutics market, providing patient-specific treatments that address individual genetic factors contributing to disease progression. As these biological therapies mature, they represent a transformative shift toward personalized and regenerative approaches in OA treatment, addressing the unmet needs of patients who have limited options with conventional therapies.

What Are the Benefits of Osteoarthritis Therapeutics for Patients and Healthcare Systems?

Osteoarthritis therapeutics offer significant benefits for patients, helping them manage chronic pain, improve joint function, and maintain their independence. Effective OA management is essential for reducing the debilitating effects of the disease, as untreated OA can lead to progressive joint damage, increased pain, and severe mobility limitations. Pain relief is a primary benefit of OA therapeutics, allowing patients to engage in daily activities with reduced discomfort. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and analgesics remain popular choices for pain management, offering quick relief and allowing patients to maintain a better quality of life. For patients with severe OA, injectable treatments like hyaluronic acid provide joint lubrication, reduce friction, and improve shock absorption, thereby reducing pain and improving function for several months. By alleviating pain and inflammation, OA therapeutics enable patients to engage in physical activity, which is essential for joint health and overall well-being.

In addition to pain management, newer osteoarthritis therapeutics, such as DMOADs, biologics, and regenerative treatments, aim to modify disease progression and potentially restore damaged joint tissues. These treatments offer the long-term benefit of slowing or halting cartilage degradation, which reduces the need for joint replacement surgeries and improves joint stability. For patients, this means fewer invasive procedures, shorter recovery times, and reduced healthcare costs associated with surgery and rehabilitation. DMOADs, still in development, are expected to address the unmet need for treatments that alter OA’s trajectory, providing patients with options that go beyond symptom relief. As disease-modifying therapies become available, they promise to deliver durable improvements in joint function, mobility, and pain management, offering a more comprehensive approach to OA care.

For healthcare systems, osteoarthritis therapeutics provide cost-saving benefits by reducing the burden of chronic disease management and elective surgeries. Joint replacement surgeries, though effective, are costly and place strain on healthcare resources. By managing OA symptoms effectively and slowing disease progression, OA therapeutics can delay or even prevent the need for joint replacement surgeries, particularly in aging populations where OA is most prevalent. This reduction in surgical demand alleviates pressure on healthcare systems and allows resources to be allocated to other areas of need. Additionally, advances in biologics and personalized treatments are expected to improve patient outcomes and reduce hospital readmissions, which further contributes to healthcare cost savings. As healthcare systems worldwide seek cost-effective solutions for managing chronic conditions, osteoarthritis therapeutics offer a practical approach to improving patient outcomes while optimizing healthcare resource allocation.

What Is Fueling the Growth in the Osteoarthritis Therapeutics Market?

The growth in the osteoarthritis therapeutics market is driven by several key factors, including the increasing prevalence of OA, advances in therapeutic options, rising demand for minimally invasive treatments, and an aging global population. As life expectancy continues to rise, OA has become more common, particularly among older adults who are prone to joint degeneration and other age-related conditions. This demographic shift has created a substantial demand for OA therapeutics, as aging individuals seek effective pain management and mobility solutions to maintain their quality of life. With OA affecting millions globally, the need for both traditional and innovative treatments has surged, driving investments in research and development for more effective and targeted therapies.

Advances in therapeutic options, particularly in the field of biologics, are also propelling market growth. The development of DMOADs, stem cell therapies, and monoclonal antibodies provides patients and healthcare providers with options that go beyond symptom relief, aiming instead to alter the course of the disease. These advanced therapies have garnered interest from both patients and healthcare professionals, as they offer the potential to slow or reverse disease progression, reducing the need for invasive procedures and providing long-lasting relief. The appeal of these innovative therapies, especially among patients who have not responded to conventional treatments, is expected to fuel demand in the OA therapeutics market as they become more widely available and affordable.

Furthermore, the trend toward minimally invasive procedures and patient-specific treatments is driving the adoption of advanced OA therapeutics. Patients are increasingly seeking treatments that offer effective symptom management with minimal disruption to their daily lives. Biological injections, such as PRP and stem cell therapy, meet this demand by providing minimally invasive options that can be administered in outpatient settings, allowing for quicker recovery times. This growing preference for non-surgical and minimally invasive treatments has encouraged pharmaceutical companies and healthcare providers to invest in alternative OA therapies that improve patient experience and outcomes. Additionally, government initiatives and insurance coverage for newer therapies are expected to support market growth, making advanced treatments more accessible to a broader patient population. Together, these factors—the aging population, advancements in therapeutic options, demand for minimally invasive treatments, and supportive healthcare policies—are driving significant growth in the osteoarthritis therapeutics market, shaping it into a dynamic and essential area of modern healthcare.

SCOPE OF STUDY:

The report analyzes the Osteoarthritis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Anatomy (Knee, Hip, Hand, Small Joints); Drug Type (Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 23 Featured) -

  • Abbott
  • Anika Therapeutics
  • Bayer AG
  • Bioventus
  • Eli Lilly
  • Fidia Farmaceutici s.p.a.
  • Flexion Therapeutics
  • GlaxoSmithKline Plc
  • Horizon Therapeutics
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Sanofi
  • Zimmer Biomet Holdings, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Economic Update
    • Osteoarthritis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Osteoarthritis Drives Demand for Therapeutics
    • Increasing Focus on Pain Management Propels Osteoarthritis Therapeutics Market
    • Advancements in Biologics and Stem Cell Therapies Expand Market Potential
    • Growing Adoption of Disease-Modifying Osteoarthritis Drugs (DMOADs) Sets the Stage for Market Growth
    • Innovations in Oral, Topical, and Injectable Therapies Propel Demand
    • Increasing Elderly Population Generates Demand for Osteoarthritis Treatment Solutions
    • Growing Interest in Non-Opioid Pain Management Expands Market Opportunities
    • Surge in Minimally Invasive Procedures Spurs Osteoarthritis Therapeutic Adoption
    • Adoption of Alternative Therapies Expands Treatment Options for Osteoarthritis
    • Increasing Demand for Over-the-Counter (OTC) Osteoarthritis Drugs Propels Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Osteoarthritis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Osteoarthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Knee by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Knee by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Knee by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hip by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hip by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Hip by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Hand by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Hand by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Hand by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Small Joints by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Small Joints by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Small Joints by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Viscosupplementation Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Viscosupplementation Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Viscosupplementation Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Nonsteroidal Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Nonsteroidal Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Nonsteroidal Anti-inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Osteoarthritis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • JAPAN
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • CHINA
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • EUROPE
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Osteoarthritis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Osteoarthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • FRANCE
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • GERMANY
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Osteoarthritis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Osteoarthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • INDIA
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Osteoarthritis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Osteoarthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Osteoarthritis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Osteoarthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030
  • AFRICA
    • Osteoarthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Osteoarthritis Therapeutics by Anatomy - Knee, Hip, Hand and Small Joints Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Osteoarthritis Therapeutics by Anatomy - Percentage Breakdown of Value Sales for Knee, Hip, Hand and Small Joints for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Osteoarthritis Therapeutics by Drug Type - Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Osteoarthritis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics and Corticosteroids for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제